Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6400-6408

  Yoo, Christine B ^a   Jeong, Shinwu ^b   Egger, Gerda ^b   Liang, Gangning ^a,b   Phiasivongsa, Pasit ^c   Tang, Chunlin ^c   Redkar, Sanjeev ^c   Jones, Peter A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SuperGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTIDINE DEAMINASE; DINUCLEOTIDE; DNA METHYLTRANSFERASE 1; FUNCTIONAL GROUP; OLIGONUCLEOTIDE; PROTEIN P16; S 110; S 112; S 52R; S 53; S 54; S 55; S 56; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEAMINATION; DNA METHYLATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG STABILITY; ENZYMATIC DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; GENE THERAPY; HUMANS; MODELS, CHEMICAL; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDES; TRIAZINES; URINARY BLADDER NEOPLASMS;

EID: 34447123203     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0251     Document Type: Article

References (48)

1. Costello JF, Plass C. Methylation matters. J Med Genet 2001;38:285-303.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
4. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
5. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989;83:155-8.
6. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
7. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991;48:880-8.
8. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, Tycko B. Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. Am J Hum Genet 1993;53:113-24.
9. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604-8.
10. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
11. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964;20:202-3.
12. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
13. Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 1982;162:679-92.
14. Beisler JA. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 1978;21:204-8.
15. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004;24:1270-8.
16. McBride L, Caruthers MH. Tet Lett 1983;24:245-8.
17. Beaucage SL, Caruthers MH. Tet Lett 1981;22:1859-62.
18. Vincenzetti S, De Sanctis G, Costanzi S, et al. Functional properties of subunit interactions in human cytidine deaminase. Protein Eng 2003;16:1055-61.
19. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
20. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302-6.
21. Gonzalgo ML, Jones PA. Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods 2002;27:128-33.
22. Gal-Yam EN, Jeong S, Tanay A, Egger G, Lee AS, Jones PA. Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet 2006;2:e160.
23. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
24. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
25. Flatau E, Gonzales FA, Michalowsky LA, Jones PA. DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol 1984;4:2098-102.
26. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
27. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7.
28. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321:591-9.
29. Hurd PJ, Whitmarsh AJ, Baldwin GS, et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 1999;286:389-401.
30. Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 1983;32:1327-8.
31. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
32. Iversen PL. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 2001;3:235-8.
33. Tafech A, Bassett T, Sparanese D, Lee CH. Destroying RNA as a therapeutic approach. Curr Med Chem 2006;13:863-81.
34. Tidd DM, Warenius HM. Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methyl-phosphonate groups. Br J Cancer 1989;60:343-50.
35. Barry ME, Pinto-Gonzalez D, Orson FM, McKenzie GJ, Petry GR, Barry MA. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 1999;10:2461-80.
36. Bernardi G, Griffe M. Studies on acid deoxyribonuclease. Ii. Isolation and characterization of spleen-acid deoxyribonuclease. Biochemistry 1964;3:1419-26.
37. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
38. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-8.
39. Gait MJ. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci 2003;60:844-53.
40. Geselowitz DA, Neckers LM. Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 1992;2:17-25.
41. Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997;3:414-20.
42. Geselowitz DA, Neckers LM. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev 1995;5:213-7.
43. Yakubov LA, Deeva EA, Zarytova VF, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci U S A 1989;86:6454-8.
44. Hanss B, Leal-Pinto E, Bruggeman LA, Copeland TD, Klotman PE. Identification and characterization of a cell membrane nucleic acid channel. Proc Natl Acad Sci U S A 1998;95:1921-6.
45. Yano Y, Hayashi Y, Sano K, et al. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (E-NPP3/CD203c/PD-I beta/B10/gp130RB13-6) in human colon carcinoma. Int J Mol Med 2003;12:763-6.
46. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006;5:660-70.
47. Beavo JA, Brunton LL. Cyclic nucleotide research: still expanding after half a century. Nat Rev Mol Cell Biol 2002;3:710-8.
48. Williams C. cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 2004;3:125-35.